Based on our expected activity in 2007, we continue to estimate our average monthly cash usage to be $1,400,000 per month (see "Liquidity and Capital Resources").
Recent 2007 Progress
On October 23, 2007, we announced receipt of a letter of approval to commence our clinical trial using intravenous administration of REOLYSIN(R) in combination with cyclophosphamide, a chemotherapeutic agent as well as immune modulator, in patients with advanced cancers.
The trial is an open-label, dose-escalating, non-randomized trial of REOLYSIN(R) given intravenously with escalating doses of cyclophosphamide. A standard dose of REOLYSIN(R) is administered intravenously over five consecutive days, while an intravenous dose of cyclophosphamide is administered three days before REOLYSIN(R) treatment and continues through the course of the treatment cycle. The total number of patients studied will depend on the number of dose levels tested, but it is anticipated to be approximately 30 patients.
Eligible patients include those who have been diagnosed with advanced
or metastatic solid tumours including pancreatic, lung and ovarian cancers
that are refractory to standard therapy or for which no curative standard
therapy exists. The primary objectives of the trial include determining the
Minimum Effective Immunomodulatory Dose of cyclophosphamide to obtain
successful immune modulation. Secondary objectives include the safety
profile of the combinatio
|SOURCE Oncolytics Biotech Inc.|
Copyright©2007 PR Newswire.
All rights reserved